Outset Medical's Next-Generation Tablo Hemodialysis System Receives FDA Clearance with Enhanced Cybersecurity
Key Insights
Outset Medical announced FDA 510(k) clearance for its next-generation Tablo hemodialysis platform, making it the first dialysis system to meet FDA's most rigorous cybersecurity guidance published in June 2025.
The enhanced platform features enterprise-grade cybersecurity embedded at hardware, software and cloud levels, along with hardware upgrades and software improvements designed to enhance reliability and user experience.
The next-generation Tablo system is expected to begin shipping to customers in the second quarter of 2026, with existing healthcare providers eligible for upgrades to the new cybersecurity platform.
Outset Medical announced on January 27, 2026, that its next-generation Tablo hemodialysis platform has received 510(k) clearance from the U.S. Food and Drug Administration, marking a significant milestone in dialysis technology cybersecurity. The San Jose-based medical technology company's enhanced platform becomes the first hemodialysis system to incorporate FDA's most rigorous and recent guidance on medical device cybersecurity, published in June 2025.
"We are proud to be the first dialysis company to clear the high standard for cybersecurity set by the FDA, a milestone that reflects Outset's ongoing commitment to innovation, patient safety and data stewardship," said Leslie Trigg, Chair and CEO of Outset Medical. "Our next-generation platform is designed to protect and amplify the clinical, financial and operational value delivered to our customers, and extend Outset's technology lead."
Enhanced Security and Performance Features
The next-generation Tablo platform has been architected to deliver enterprise-grade cybersecurity, reliability, and usability across multiple healthcare settings. The system incorporates security measures embedded at the hardware, software and cloud levels, designed to meet current hospital information technology standards.
Beyond cybersecurity enhancements, the platform features significant performance improvements through operating system modernization, hardware upgrades and software advancements. These enhancements are designed to improve system performance and lengthen the time between planned maintenance in high-acuity environments.
The updated system also includes exterior enhancements aimed at providing hospital-grade durability that can withstand the rigors of acute care environments, addressing the demanding operational requirements of hospital-based dialysis programs.
Market Impact and Deployment Timeline
The next-generation Tablo platform is expected to begin shipping to customers in the second quarter of 2026. Healthcare providers currently using the existing Tablo system will be eligible to upgrade to the new cybersecurity-enhanced platform, ensuring continuity of care while improving security standards.
Outset Medical's Tablo Hemodialysis System is currently FDA-cleared for use from hospital to home settings and is trusted by more than 1,000 U.S. healthcare facilities. The system has enabled millions of treatments delivered by thousands of nurses across the continuum of care.
Technology Integration and Clinical Value
The Tablo system combines water purification and on-demand dialysate production into a single, integrated platform that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution is designed to reduce the cost and complexity of dialysis while empowering healthcare providers to develop in-house dialysis programs with greater operational control.
The integrated approach enables healthcare providers to achieve better operational, clinical, and financial outcomes by maintaining control over their dialysis programs rather than relying on external dialysis centers. This model represents a shift toward more flexible and cost-effective dialysis care delivery across hospital and home settings.